Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Telsey Advisory Group Maintains Outperform on Enjoy Technology, Lowers Price Target to $11

Telsey Advisory Group analyst Dana Telsey maintains Enjoy Technology (NASDAQ:ENJY) with a Outperform and lowers the price target from $14 to $11.

byBenzinga Newsdesk

November 12, 2021

1 minute read

Telsey Advisory Group analyst Dana Telsey maintains Enjoy Technology (NASDAQ:ENJY) with a Outperform and lowers the price target from $14 to $11.

Apple’s Epic Loss Could Be A Game Changer For Spotify

By IAM Newswire

Today, 6:29 AM

Last week, Apple (NASDAQ: AAPL) lost a court case to Fortnite creator Epic Games and was ordered to allow developers to send their app's users to outside payment systems.

AAPL

Deutsche Bank Initiates Coverage On Global Ship Lease with Buy Rating, Announces Price Target of $23

By Benzinga Newsdesk

Today, 6:29 AM

Deutsche Bank initiates coverage on Global Ship Lease (NYSE:GSL) with a Buy rating and announces Price Target of $23.

GSL

SVB Leerink Maintains Market Perform on BioNTech, Lowers Price Target to $268

By Benzinga Newsdesk

Today, 6:29 AM

SVB Leerink analyst Daina Graybosch maintains BioNTech (NASDAQ:BNTX) with a Market Perform and lowers the price target from $293 to $268.

BNTX

Ocular Therapeutix Q1 EPS $(0.22) Beats $(0.26) Estimate, Sales $13.19M Miss $14.20M Estimate

By Benzinga Newsdesk

Today, 6:29 AM

Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.26) by 15.38 percent. This is a 8.33 percent increase over losses of $(0.24) per share from

OCUL

Telsey Advisory Group Maintains Outperform on Enjoy Technology, Lowers Price Target to $11

Related Posts

Apple’s Epic Loss Could Be A Game Changer For Spotify

Deutsche Bank Initiates Coverage On Global Ship Lease with Buy Rating, Announces Price Target of $23

SVB Leerink Maintains Market Perform on BioNTech, Lowers Price Target to $268

Ocular Therapeutix Q1 EPS $(0.22) Beats $(0.26) Estimate, Sales $13.19M Miss $14.20M Estimate